



200.1102CP2

#9
YC
2-2703

UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Todd WARE

Art Unit: 1615

Re: Application of:

Robert F. KAIKO, et al.

Serial No.:

09/992,936

Filed:

November 5, 2001

For:

**OPIOID AGONIST/OPIOID ANTAGONIST/
ACETAMINOPHEN COMBINATIONS**

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

January 30, 2003

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97(b), Applicants hereby make of record the references listed on the accompanying Form PTO-1449 (10 pages).

Applicants respectfully advise the Examiner of the following U.S. Patent and co-pending U.S. Patent Applications which are commonly assigned to the owners of the instant application:

U.S. Application Serial No. 10/244,783, filed September 16, 2002, entitled "Opioid agonist/antagonist combinations" which is a continuation of U.S. Application Serial No. 09/815,167, filed March 22, 2001, now U.S. Patent No. 6,475,494, which is a continuation of U.S. Application Serial No. 09/218,662, filed December 22, 1998, now U.S. Patent No. 6,277,384.

U.S. Application Serial No. 09/815,162, filed March 22, 2001, entitled "Method of preventing abuse of opioid dosage forms" which is a continuation of U.S. Application Serial No. 09/218,663, filed December 22, 1998, now U.S. Patent No. 6,228,863.

U.S. Application Serial No. 09/781,081, filed February 8, 2001, entitled "Tamper-resistant oral opioid agonist formulations".

U.S. Application Serial No. 09/781,076, filed February 8, 2001, entitled "Controlled released compositions containing an opioid agonist and antagonist".

U.S. Application Serial No. 10/199,972, filed July 18, 2002, entitled "Pharmaceutical combinations of oxycodone and naloxone".

The Examiner's attention is respectfully directed to the following references of record, which were cited by the Examiner during the prosecution of U.S. Application Serial No.

09/218,663, filed December 22, 1998, now U.S. Patent No. 6,228,863:

AC (U.S. Patent No. 5,624,932 to Qin et al.);
HB (U.S. Patent No. 5,633,259 to Qin et al.);
EC (U.S. Patent No. 5,472,943 to Crain et al.);
EE (U.S. Patent No. 5,512,578 to Crain et al.);
EK (U.S. Patent No. 5,580,876 to Crain et al.);
AB (U.S. Patent No. 5,767,125 to Crain et al.);
HC (U.S. Patent No. 5,866,164 to Kuczynski et al.); and
HN (Walsh et al.).

The Examiner's attention is also respectfully directed to the following references of record, which were cited by the Examiner during the prosecution of U.S. Application Serial No. 09/218,662, filed December 22, 1998, now U.S. Patent No. 6,277,384:


EE (U.S. Patent No. 5,512,578 to Crain et al.); and
AM (Hanson) at page 1 of 1.

Pursuant to 37 C.F.R. § 1.98(d), copies of the references listed on the accompanying Form PTO-1449 (10 pages) are of record in the parent application (U.S. Application Serial No. 09/503,020, filed February 11, 2000, now U.S. Patent No. 6,375,957) and are not enclosed. If it is determined that any of the listed references are not of record in the parent application, the Examiner is requested to contact the undersigned so that a copy can be forwarded.

This Information Disclosure Statement and accompanying Form PTO-1449 are being filed under C.F.R. § 1.97(b)(4) before the mailing of a first Office Action after the filing of a request for Continued Examination under § 1.114. Accordingly, no fee is due. In the event any fee is due or overpayment made in connection with the filing of this Information Disclosure Statement, the Assistant Commissioner is hereby authorized to charge said deficiency or credit overpayment to our Deposit Account No. 50-0552.

It is respectfully requested that the references cited in the accompanying Form PTO-1449 be considered and made of record.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By 
Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940